All In Biotech

Drug Trial Radar · NCT06765161

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Feb 6, 2025

Primary completion

Jan 6, 2027

Study completion Jan 6, 2027

Sponsor

Lead sponsor
Clinique Neuro-OutaouaisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
argenx
First posted
Jan 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.

Conditions

  • Myasthaenia Gravis

Interventions

  • efgartigimod administrationDrug

    efgartigimod infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MG-ADLTime frame: a sustained decrease persistent for at least 4 consecutive weeks over the 26 week period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinique Neuro-Outaouais

    Gatineau, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.